Media ReleasesNoxopharm

View All Noxopharm News

Noxopharm Announces Idronoxil Data Provides Hope to Treat Secondary Brain Cancers

- Secondary brain cancer major cause of death in patients with breast cancer, lung cancer and melanoma

- Secondary brain cancer at least 3-times incidence of primary brain cancer

- Limited treatment options, poor survival prospects

- Idronoxil now shown to make brain cancer drug more effective by up to 1000-times.

Sydney, 19 June 2017: Noxopharm announces that it has taken an important first step in its objective of using its front-line drug, NOX66, to treat secondary cancers of the brain, in what is considered by the Company to be a world-first opportunity.

For further information please download PDF attached: 
Download this document